Athersys (NASDAQ:ATHX) Now Covered by StockNews.com

Analysts at StockNews.com initiated coverage on shares of Athersys (NASDAQ:ATHX) in a research note issued to investors on Saturday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

Athersys Price Performance

Athersys has a 12 month low of $0.01 and a 12 month high of $1.99. The company has a market capitalization of $833,000.00, a price-to-earnings ratio of 0.00 and a beta of -0.90.

About Athersys

Athersys, Inc, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.